Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision.
Everaert B, Wykrzykowska JJ, Koolen J, van der Harst P, den Heijer P, Henriques JP, van der Schaaf R, de Smet B, Hofma SH, Diletti R, Weevers A, Hoorntje J, Smits P, van Geuns RJ. Everaert B, et al. Among authors: hofma sh. Neth Heart J. 2017 Jul;25(7-8):419-428. doi: 10.1007/s12471-017-1014-z. Neth Heart J. 2017. PMID: 28643297 Free PMC article.
Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Lemos PA, et al. Among authors: hofma sh. Circulation. 2004 Jan 20;109(2):190-5. doi: 10.1161/01.CIR.0000109138.84579.FA. Epub 2003 Dec 22. Circulation. 2004. PMID: 14691037 Clinical Trial.
Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction.
Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, Hoye A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. Lemos PA, et al. Among authors: hofma sh. J Am Coll Cardiol. 2004 Feb 18;43(4):704-8. doi: 10.1016/j.jacc.2003.12.022. J Am Coll Cardiol. 2004. PMID: 14975486 Free article. Clinical Trial.
Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study.
Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PW. Lemos PA, et al. Among authors: hofma sh. Circulation. 2004 Mar 23;109(11):1366-70. doi: 10.1161/01.CIR.0000121358.26097.06. Epub 2004 Mar 1. Circulation. 2004. PMID: 14993127
Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery.
Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, Hofma S, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. Hoye A, et al. Coron Artery Dis. 2004 May;15(3):171-5. doi: 10.1097/00019501-200405000-00006. Coron Artery Dis. 2004. PMID: 15096998 Free article. Clinical Trial.
Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions.
Hoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, Degertekin M, Hofma SH, Sianos G, McFadden E, van der Giessen WJ, Smits PC, de Feyter PJ, van Domburg RT, Serruys PW. Hoye A, et al. Among authors: hofma sh. J Am Coll Cardiol. 2004 Jun 2;43(11):1954-8. doi: 10.1016/j.jacc.2004.01.045. J Am Coll Cardiol. 2004. PMID: 15172397 Free article.
97 results